Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Gilead Sciences (NASDAQ:GILD) Chairman and CEO Daniel O’Day sold 10,000 shares of company stock on June 30, 2025, for approximately $1.1 million. The sales were executed in two transactions. The sale comes as Gilead, currently valued at $138.87 billion, shows strong momentum with a 68% return over the past year.
The first transaction involved 9,400 shares sold at an average price of $110.4038, with prices ranging from $110.03 to $111.00, for a total value of $1,037,796. The second transaction involved 600 shares sold at an average price of $111.1467, with prices ranging from $111.03 to $111.17, for a total value of $66,688. According to InvestingPro analysis, the stock is currently trading near its 52-week high, with a "GREAT" overall financial health score.
Following these transactions, O’Day directly owns 615,725 shares of Gilead Sciences.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025.
In other recent news, Gilead Sciences has made significant strides with the FDA’s approval of Yeztugo, an injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis. This approval marks Yeztugo as the first and only twice-yearly option available in the United States for HIV prevention, potentially expanding the PrEP market. BMO Capital has reiterated an Outperform rating for Gilead Sciences, highlighting the drug’s potential to drive growth in its PrEP business. In addition, RBC Capital raised its price target for Gilead Sciences to $95, citing positive factors that could drive the adoption of lenacapavir, despite some challenges in market expansion.
Meanwhile, Gilead Sciences has entered into a collaboration with Kymera Therapeutics to develop a novel cancer drug targeting cyclin-dependent kinase 2 (CDK2). Under this agreement, Kymera could receive up to $750 million in payments, with Gilead gaining global rights to any resulting products if it exercises its option. The partnership aims to offer more precise cancer treatment by removing the CDK2 protein rather than inhibiting its function. These developments reflect Gilead’s ongoing efforts to expand its portfolio in both HIV prevention and cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.